Klinikum Augsburg (Augsburg, DE), Medical Department II, Germany.
Epigenomics. 2011 Oct;3(5):611-23. doi: 10.2217/epi.11.80.
Allogeneic hematopoietic stem cell transplantation is a high risk but curative treatment option for leukemia, myelodysplasia and other hematological malignancies. After high dose radio- or chemo-therapy, recipient's hematopoiesis is replaced by a new immunosystem and residual malignant cells are eliminated by the graft-versus-leukemia reaction. The benefit of this immunological effect is limited by the most frequent complication of hematopoietic stem cell transplantation: graft-versus-host disease. In addition to their well-known anti-tumor activity, epigenetic drugs mediate immunotolerance without reducing alloreactivity or even enhance graft-versus-leukemia effect without inducing graft-versus-host disease by regulating cytokine release, increasing the circulating number of regulatory T cells and interacting with natural killer cells. We focus on the use of epigenetic drugs in the allogeneic transplantation setting in relation to their anti-tumor and immunomodulatory potential.
异基因造血干细胞移植是白血病、骨髓增生异常和其他血液系统恶性肿瘤的一种高风险但有治愈可能的治疗选择。在大剂量放化疗后，受者的造血功能被新的免疫系统所取代，移植物抗白血病反应消除残留的恶性细胞。这种免疫效应的益处受到造血干细胞移植最常见并发症的限制：移植物抗宿主病。除了众所周知的抗肿瘤活性外，表观遗传药物通过调节细胞因子释放、增加调节性 T 细胞的循环数量以及与自然杀伤细胞相互作用来介导免疫耐受，而不降低同种异体反应性，甚至在不诱导移植物抗宿主病的情况下增强移植物抗白血病效应。我们专注于在同种异体移植环境中使用表观遗传药物，以发挥其抗肿瘤和免疫调节潜力。
